Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May;11(5):1945-1962.
doi: 10.21037/jtd.2019.04.97.

Transcatheter versus surgical aortic valve replacement in low and intermediate risk patients with severe aortic stenosis: systematic review and meta-analysis of randomized controlled trials and propensity score matching observational studies

Jintao Fu  1 , Mohammad Sharif Popal  1 , Yulin Li  1 , Guoqi Li  1 , Yue Qi  1 , Fang Fang  1 , Joey S W Kwong  2 , Bin You  1 , Xu Meng  1 , Jie Du  1
Affiliations

Transcatheter versus surgical aortic valve replacement in low and intermediate risk patients with severe aortic stenosis: systematic review and meta-analysis of randomized controlled trials and propensity score matching observational studies

Jintao Fu et al. J Thorac Dis. 2019 May.

Abstract

Background: To compare the outcome of transcatheter aortic valve replacement (TAVR) with surgical aortic valve replacement (SAVR) in low and intermediate risk patients with severe aortic stenosis (AS). Randomized controlled trials (RCT) and propensity score matching (PSM) studies compare TAVR with SAVR in patients at low and intermediate surgical risk.

Methods: Two authors searched relevant literature independently, then extracted data from the included studies, and assessed risk of bias and quality of study separately according to different study designs, besides that, the extracted data was analyzed via utilization of GRADE system to evaluate the quality of evidence separately.

Results: Overall 15 studies (5 RCTs, 10 PSM studies) with total 12,057 patients were selected. Mortality and disabling stroke during follow-up period were comparable between TAVR and SAVR (RR 1.09, 95% CI: 0.81 to 1.46; RR 0.7, 95% CI: 0.45 to 1.07, respectively), TAVR revealed to be superior to SAVR regarding acute kidney injury (AKI), and onset of new atrial fibrillation (AF) (RCT: high certainty; AKI in PSM: moderate certainty, AF in PSM: low certainty). These results of RCT and PSM studies are consistent. In RCT review, SAVR was better in the following aspects: aortic valve (AV) re-intervention (high certainty), vascular complications, pacemaker implantation (moderate certainty), but comparable in the following aspects: myocardial infarction (MI), aortic insufficient (AI) (moderate certainty), major bleeding (low certainty). In PSM review, SAVR revealed a better result in AI and vascular complications (high certainty), but in the aspects of AV re-intervention, pacemaker implantation, major bleeding and MI (low certainty), it was comparable.

Conclusions: TAVR is comparable to SAVR in terms of mortality and disabling stroke in severe AS patients at low and intermediate risk, but higher proportion of AV re-intervention observed in TAVR. Those results should encourage caution when extending the indications of TAVR into low risk patients, especially for young low risk patients.

Systematic review registration: PROSPERO CRD 42018112626.

Keywords: Transcatheter aortic valve replacement (TAVR); low and intermediate risk; meta-analysis; severe aortic stenosis; surgical aortic valve replacement (SAVR).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Flowchart of study selection.
Figure 2
Figure 2
Risk of bias summary in RCT studies. RCT, randomized controlled trials.
Figure 3
Figure 3
Thirty days all-cause mortality.
Figure 4
Figure 4
One-year all-cause mortality.
Figure 5
Figure 5
Two-year all-cause mortality.
Figure 6
Figure 6
Three-year all-cause mortality.
Figure 7
Figure 7
Thirty days disabling stroke.
Figure 8
Figure 8
One-year disabling stroke.
Figure 9
Figure 9
Thirty days AV re-intervention. AV, aortic valve.
Figure 10
Figure 10
One-year AV re-intervention. AV, aortic valve.
Figure 11
Figure 11
Two-year AV re-intervention. AV, aortic valve.
Figure 12
Figure 12
Thirty days AI (moderate or more). AI, aortic insufficient.
Figure 13
Figure 13
Thirty days vascular complications.
Figure 14
Figure 14
Thirty days AKI. AKI, acute kidney injury.
Figure 15
Figure 15
Thirty days major bleeding.
Figure 16
Figure 16
One-year new onset AF. AF, atrial fibrillation.
Figure 17
Figure 17
One-year permanent pacemaker implantation.
Figure 18
Figure 18
One-year MI. MI, myocardial infarction.
Figure S1
Figure S1
GRADE assessment of quality of evidence (RCT review).
Figure S2
Figure S2
GRADE assessment of quality of evidence (PSM review).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Goldbarg SH, Elmariah S, Miller MA, et al. Insights into degenerative aortic valve disease. J Am Coll Cardiol 2007;50:1205-13. 10.1016/j.jacc.2007.06.024 - DOI - PubMed
    1. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet 2006;368:1005-11. 10.1016/S0140-6736(06)69208-8 - DOI - PubMed
    1. Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003;24:1231-43. 10.1016/S0195-668X(03)00201-X - DOI - PubMed
    1. Carabello BA, Paulus WJ. Aortic stenosis. Lancet 2009;373:956-66. 10.1016/S0140-6736(09)60211-7 - DOI - PubMed
    1. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease(version 2012):the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 2012;42:S1-44. - PubMed